香雪製藥(300147.SZ):擬將兆陽生物分立後的100%股權轉讓給知識城集團
格隆匯10月15日丨香雪製藥(300147.SZ)公佈,此前披露,公司第八屆董事會第三十四次會議,審議通過了《關於全資子公司存續分立的議案》,對全資子公司廣東兆陽生物科技有限公司(“兆陽生物”)進行了存續分立。兆陽生物保留原有的在建工程、無形資產及部分負債,新公司承接了兆陽生物原有的與生物製品相關的業務及部分資產和負債,以及持有對外投資公司的股權。截至公吿出具日,兆陽生物已辦理了分立變更登記,取得了新的工商營業執照。
為進一步聚焦主營業務的發展,整合優化資產結構及資源配置,提高資產流動性及使用效率,增強核心競爭力,公司與知識城(廣州)投資集團有限公司(“知識城集團”)簽署了《知識城(廣州)投資集團有限公司與廣州市香雪製藥股份有限公司、廣東兆陽生物科技有限公司之股權轉讓協議書》,通過股權轉讓的方式將兆陽生物分立後的100%股權以1994.94萬元轉讓給知識城集團。
此次交易完成後,兆陽生物將不再納入公司合併報表範圍核算,經公司財務部門初步測算,預計增加2021年淨利潤約1177萬元,不會對公司財務狀況和經營成果產生重大影響,此次交易的具體收益以2021年度審計報吿中披露的數據為準。
公司根據業務發展規劃和實際經營需要轉讓兆陽生物的股權,整合優化了資產結構及資源配置,提高了資產流動性及使用效率,有利於公司聚焦主營業務的發展,增強核心競爭力,同時也進一步完善了公司的管理體系與股權架構,降低了經營及管理成本,為公司帶來了正向的流動資金和合作收益,符合公司整體戰略發展規劃。此次股權轉讓獲得的資金將用於補充公司流動資金,有利於改善公司現金流,符合公司實際經營和未來發展需要,不存在損害上市公司和股東、特別是中小股東利益的情形。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.